Misonidazole
Misonidazole is a radiosensitizer that was investigated in clinical trials. It was used in these trials for radiation therapy to cause normally resistant hypoxic tumor cells to become sensitive to the treatment.[1][2]
|  | |
| Names | |
|---|---|
| IUPAC name (RS)-1-Methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol | |
| Identifiers | |
| 3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.033.559 | 
| EC Number | 
 | 
| KEGG | |
| MeSH | D008920 | 
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| 
 | |
| 
 | |
| Properties | |
| C7H11N3O4 | |
| Molar mass | 201.182 g·mol−1 | 
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references | |
See also
    
    
References
    
- Meißner, Rebecca; Feketeová, Linda; Illenberger, Eugen; Denifl, Stephan (2019). "Reactions in the Radiosensitizer Misonidazole Induced by Low-Energy (0–10 eV) Electrons". International Journal of Molecular Sciences. 20 (14): 3496. doi:10.3390/ijms20143496. PMC 6678818. PMID 31315268.
- Overgaard, Jens (2011). "Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis". Radiotherapy and Oncology. 100 (1): 22–32. doi:10.1016/j.radonc.2011.03.004. PMID 21511351.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

